The complete amino acid sequence of human serum paraoxonase/arylesterase and the DNA sequence coding for that protein have recently been determined in two independent laboratories. There is now considerable evidence that the esterase exists in two genetically determined allozymic forms, and these A and B allozymes possess both paraoxonase and arylesterase activities. The B-type esterase has relatively higher paraoxonase activity and is stimulated to a greater degree by 1 M NaC1 than the A allozyme. The structural basis for the distinctive isozymic properties is a single nucleotide base at position 572. Codon 191 is CAA (for glutamine) in the A-type esterase, and CGA (for arginine) in the B-type enzyme. There is a second polymorphic site which affects amino acid 54; this can be either methionine or leucine, but these alternatives have not been found to affect either the level or the quality of the allozymes. Purified A or B-type esterases are stimulated by the addition of phosphatidylcholine. The latter addition increases the maximum velocity rate, but does not alter the Km of the reaction with either paraoxon or phenylacetate. In serum, the esterase is tightly bound to the high density lipoproteins, particularly apo A-l, but the importance of this association as far as the stability and catalytic properties of the esterase is not clear, and still under study. No physiological role of the esterase has been established, but its ability to hydrolyze several potent organophosphates may be of some significance in protecting against organophosphate toxicity.
INTRODUCTION
Molecular biology studies on paraoxonase/arylesterase over the last two years in our laboratory [1] and by Furlong's group [2] have supported the model we proposed in 1983 [3] : that the human serum esterase exists in two closely related isozymic forms (A and B); that the two allozymes can hydrolyze both organophosphates and aromatic esters such as phenylacetate; and that isozyme B has a much higher turnover number for paraoxon than isozyme A. The affinity of the esterase in serum for binding tightly with other lipoproteins and to aggregate with such components may explain why another laboratory described several molecular forms of the esterase in serum, some of which appeared to have only paraoxonase or arylesterase activity [4] . However, the cloning and sequencing of the cDNA coding for the enzyme in the two laboratories leaves little doubt that two major isozymic forms (A and B) must be responsible in some way for what appear to be contrary observations from other laboratories (see La Du [5] ).
The enzyme has been highly purified from human serum in our laboratory and has a molecular weight of about 43.0 kDa [6] . It requires calcium for stability as well as its catalytic activity with either phenylacetate or paraoxon. Our method of purification of the enzyme and the basic characteristics of the isozymes have recently been published [6, 7] . Several laboratories have estimated the allelic frequencies of the paraoxonase polymorphism in ethnic groups in different parts of the world [8] [9] [10] [11] , but most of these estimates are based on measuring paraoxonase levels, alone, rather than by a method which distinguishes individual phenotypes (see La Du [5] ). The recent progress in the molecular analyses of the polymorphism should make it simpler to relate phenotypes and genotypes, and estimate allelic frequencies more accurately. The molecular studies have not yet helped us to understand the possible physiological function of the esterase, its significance in endogenous metabolism, or its close association with the HDL complex.
This report will summarize some of the recent molecular and catalytic studies on human serum paraoxonase/arylesterase in our laboratory.
MATERIALS AND METHODS
Paraoxonase/arylesterase was purified from human serum previously phenotyped so that individual units of the same A, AB, or B phenotype could be pooled. The purification method was developed in our laboratory [6] , and we were able to obtain large quantities of enzyme of over 50% purity, with small amounts of albumin and apolipoprotein A-1 as impurities. Estimates of paraoxonase and arylesterase activities and the phenotyping of individual sera were carried out as described previously [3, 12] . Ratios of paraoxonase activity in the presence of 1 M NaC1 divided by the arylesterase activity were used to identify individual phenotypes, as follows: type A, 1.21 ± 0.19; type AB, 4.68 ± 0.85, and type B, 8.36 ± 0.07 (means ± S.D.).
For sequencing of the DNA in the polymorphic regions, DNA was isolated from blood samples (buffy coat) by the salt-chloroform extraction method of Mullenbach [13] . Both polymorphic sites were near intron-exon junctions, so PCR primers were used which bridged the junctions to amplify the regions corresponding to amino acids 54 and 191. These gave products of about 180 and 230 base pairs (bp), respectively. Sequencing primers synthesized by the University of Michigan DNA Sequencing Facility and Oligos Etc. (Wilson, OR) were then used for direct sequencing of the polymorphic segments after PCR amplification to determine individual genotypes, as we recently reported [14] . Phospholipids tested for their effects on arylesterase and paraoxonase activities with purified serum esterase were obtained from Sigma Chemical Co., St. Louis, MO. These were mixed in a buffer and dispersed by sonication, then premixed with preparations of the esterase at 37 °C for about 30 rain before the enzymatic assays.
RESULTS AND DISCUSSION

Amino acid sequence of human serum paraoxonase/arylesterase
The amino acid sequence of the mature protein and the location of the two polymorphic sites of human serum paraoxonase/arylesterase are shown in Fig.  1 . Although the amino acid sequence shown has been deduced from our analyses of genomic DNA and liver cDNA nucleotide sequences, nearly 45% of the total amino acid sequence was confirmed in our laboratory by direct sequencing of tryptic and peptic digest peptides derived from the purified esterase [14] . Evidence for the polymorphism at position 191 was also obtained from high pressure liquid chromatography analysis of unique peptides identified in the tryptic digest profiles from purified A-and B-type esterases [14, 15] .
One interesting feature of the esterase structure, as first noted by Hassett et al. [2] , is the unusual concentration of hydrophobic amino acid residues at the amino terminal end of the protein. It appears to represent the retention of a modified leader sequence. Presumably, a mutation altered the leader sequence and prevented removal of this hydrophobic region. No doubt, its presence helps account for the tendency of this protein to bind to other proteins, and aggregate by itself.
There are 354 amino acids in the mature protein with only 3 cysteine residues. Two of these are near the ends of the protein; the third is residue number 283. In our sequencing of tryptic digest peptides from purified esterase without reduction, a disulfide bridge linking two tryptic peptides was found. One of these was at the amino terminal end, and the other was near the carboxyl terminal position (Fig. 2 ). These were subsequently sequenced after reduction and separation to verify their locations. These results suggest that the ends of the native protein are linked by a disulfide bond, and this would leave only the cysteine at position 283 as the likely candidate for being a key component in the active center of this esterase.
Analysis of the structural polymorphisms
Variations in the amino acid residues at positions 54 and 191 were noticed by GCG  CTC  ACC  CTC  TTG  GGG  ATG  GGA  CTG  GCA  CTC  TTC  AGG  AAC  CAC  CAG  TCT  TCT  TAC  CAA  ACA   L30  p35  A40  15 Leu  GTG  TTG  CAA  CGC  AGT  ACA  GTT  GCC  TCT  GTG  TAC  AAA  GGG  AAA  CTC  CTG  ATT  GGC  ACA  GTG  T?T  CAC  AAA  GCT Furlong's laboratory [2] and our laboratory [14, 15] . At amino acid residue 54, it was methionine or leucine, and at position 191 it was glutamine or arginine.
The two residues at one of these positions, alone, might explain the paraoxonase/arylesterase polymorphism, or certain combinations within the four isomers could be required. It was thus necessary to compare the genotypes obtained by direct sequencing of the PCR amplified genomic DNA at the two polymorphic sites with phenotyping results from serum of the same individuals. Blood samples from twenty-seven unrelated volunteers were phenotyped by their ratios of paraoxonase activity in the presence of 1 M NaC1 divided by their arylesterase activity (Fig. 3) , and their DNA samples were used to sequence the two polymorphic regions after PCR amplification. The results of these analyses Ratio of PX activity/ PA activity are shown in Table I . Comparison of the serum esterase phenotypes and the DNA analyses showed that the amino acid at position 191 coincided exactly with the serum enzyme phenotype in every individual. All those of phenotype A had glutamine, and those of phenotype B all had arginine at position 191; heterozygous individuals (AB) had both of these amino acids represented. On the other hand, the methionine/leucine polymorphism determined by the codon for position 54 did not affect the serum phenotype in any obvious way. It is of interest that all B-type individuals were homozygous for leucine at the latter site, but this may simply be the result of linkage disequilibrium since these genetic markers are very close. The perfect agreement between the amino acids at position 191 and the serum esterase phenotypes in the individuals indicates that gene frequencies estimated from either of these traits would be the same. In contrast, the frequencies of the methionine/leucine polymorphic choices at residue 54 did not show a similar agreement. It is, none the less, a very common polymorphism, and its importance must still be determined. A schematic representation of the enzyme structure showing the free sulfhydryl group (cysteine), the single internal disulfide bridge, the two polymorphic sites, and the location of four possible carbohydrate chains based on the requisite amino acid sequence is shown in Fig. 4 .
Stimulation of esterase activity by phospholipids
It has been observed that with higher purification of the serum paraox- onase/arylesterase some loss of activity regularly takes place, but this loss can be largely regained by adding back certain fractions obtained during the DEAE column chromatography step. We analyzed these fractions and found that they were enriched in phospholipids. When we substituted purified dilauroyl phosphatidylcholine, a maximal degree of stimulation was obtained (Table II) . Commercial lecithin preparations and most other phospholipids were somewhat less effective; phosphatidyl-serine was inhibitory. A comparison of the effectiveness of the compounds shows that there is some degree of specificity for this effect, and saturated medium length fatty acids were more effective than the other analogs. We now suspect that some of our earlier observations on protective or stimulatory effects obtained by combining apolipoprotein A-1 with the purified esterase were probably due to the phospholipid content of the mixture. We have yet to see a clear beneficial effect of apolipoprotein A-1 with the purified esterase when there is also an optimal concentration of choline-containing phospholipids. Among the compounds not effective in place of the phosphatidylcholine were tripalmitin, sphingomyelin, and phosphatidylinositol. Simple lipids, then, are not all stimulatory like selective phospholipids. Dilauroyl phosphatidylcholine does not change the Km appreciably, but it increases the Vmax of the reaction. Thus, the phosphatidylcholine is not simply facilitating the interaction of substrate with the enzyme, but is making the enzyme a more efficient catalyst, and presumably is increasing the turnover number of the esterase with either paraoxon or phenylacetate (Fig. 5) .
The very close association of serum paraoxonase/arylesterase with apolipoprotein A-1 and with phosphatidylcholine may take place through the hydrophobic region at the amino terminus of the enzyme. However, a more exact understanding of the interactions of the esterase with these components will be possible after we obtain the three-dimensional characteristics of the molecule by crystallographic analysis. 
